377 related articles for article (PubMed ID: 14766247)
21. Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer.
Brandt S; Kopp A; Grage B; Knabbe C
Anticancer Res; 2003; 23(1A):223-9. PubMed ID: 12680217
[TBL] [Abstract][Full Text] [Related]
22. [Expression of estrogen receptor beta mRNA in endometrial carcinoma and its significance].
Wen H
Zhonghua Fu Chan Ke Za Zhi; 2001 Feb; 36(2):108-10. PubMed ID: 11783346
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of endometrial carcinoma cell growth using antisense estrogen receptor oligodeoxyribonucleotides.
Taylor AH; al-Azzawi F; Pringle JH; Bell SC
Anticancer Res; 2002; 22(6C):3993-4003. PubMed ID: 12553024
[TBL] [Abstract][Full Text] [Related]
24. Estrogen receptor beta expression in invasive breast cancer.
Mann S; Laucirica R; Carlson N; Younes PS; Ali N; Younes A; Li Y; Younes M
Hum Pathol; 2001 Jan; 32(1):113-8. PubMed ID: 11172304
[TBL] [Abstract][Full Text] [Related]
25. Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?
Speirs V; Parkes AT; Kerin MJ; Walton DS; Carleton PJ; Fox JN; Atkin SL
Cancer Res; 1999 Feb; 59(3):525-8. PubMed ID: 9973193
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis.
Pujol P; Rey JM; Nirde P; Roger P; Gastaldi M; Laffargue F; Rochefort H; Maudelonde T
Cancer Res; 1998 Dec; 58(23):5367-73. PubMed ID: 9850067
[TBL] [Abstract][Full Text] [Related]
27. [Estrogen and progesterone receptors in endometrial carcinoma].
Guo Y; Dang Q
Zhonghua Fu Chan Ke Za Zhi; 1997 Jul; 32(7):418-21. PubMed ID: 9639729
[TBL] [Abstract][Full Text] [Related]
28. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors.
Lindgren P; Bäckström T; Mählck CG; Ridderheim M; Cajander S
Int J Oncol; 2001 Jul; 19(1):31-8. PubMed ID: 11408919
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.
Speirs V; Malone C; Walton DS; Kerin MJ; Atkin SL
Cancer Res; 1999 Nov; 59(21):5421-4. PubMed ID: 10554009
[TBL] [Abstract][Full Text] [Related]
30. Expression of Rb2/p130 in breast and endometrial cancer: correlations with hormone receptor status.
Milde-Langosch K; Goemann C; Methner C; Rieck G; Bamberger AM; Löning T
Br J Cancer; 2001 Aug; 85(4):546-51. PubMed ID: 11506494
[TBL] [Abstract][Full Text] [Related]
31. [Effects of mifepristone on expression of estrogen receptor and progesterone receptor in cultured human eutopic and ectopic endometria].
Jiang J; Wu R; Wang Z
Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):218-21. PubMed ID: 11783365
[TBL] [Abstract][Full Text] [Related]
32. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators.
Lim P; Aquino-Parsons CF; Wong F; Dupuis B; Phillips D; Zhou C; Gilks CB
Gynecol Oncol; 1999 May; 73(2):191-5. PubMed ID: 10329033
[TBL] [Abstract][Full Text] [Related]
33. [Study on expression of PCNA and estrogen, progesterone receptors in endometrial carcinoma].
Chen YP; Shen M; Chen C
Hunan Yi Ke Da Xue Xue Bao; 2001 Apr; 26(2):123-5. PubMed ID: 12536641
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological significance of fragile histidine triad transcription protein expression in endometrial carcinomas.
Segawa T; Sasagawa T; Saijoh K; Inoue M
Clin Cancer Res; 2000 Jun; 6(6):2341-8. PubMed ID: 10873085
[TBL] [Abstract][Full Text] [Related]
35. [Endocrinological contribution for invasion and metastasis in gynecological cancers].
Fujimoto J
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):633-43. PubMed ID: 8808831
[TBL] [Abstract][Full Text] [Related]
36. The influence of hormones on CD44 expression in endometrial and breast carcinomas.
Durst B; Sorg RV; Röder G; Betz B; Beckmann MW; Niederacher D; Bender HG; Dall P
Oncol Rep; 2001; 8(5):987-93. PubMed ID: 11496303
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor expression is a common feature of ovarian borderline tumors.
Abu-Jawdeh GM; Jacobs TW; Niloff J; Cannistra SA
Gynecol Oncol; 1996 Feb; 60(2):301-7. PubMed ID: 8631556
[TBL] [Abstract][Full Text] [Related]
38. Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry.
Kuo DY; Mallick S; Shen HJ; DeVictoria C; Jones J; Fields AL; Goldberg GL; Runowicz CD; Horwitz SB
Clin Cancer Res; 1996 Dec; 2(12):1981-92. PubMed ID: 9816157
[TBL] [Abstract][Full Text] [Related]
39. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma.
Nyholm HC; Christensen IJ; Nielsen AL
Gynecol Oncol; 1995 Dec; 59(3):347-51. PubMed ID: 8522253
[TBL] [Abstract][Full Text] [Related]
40. bcl-2 and p53 in endometrial adenocarcinoma.
Taskin M; Lallas TA; Barber HR; Shevchuk MM
Mod Pathol; 1997 Jul; 10(7):728-34. PubMed ID: 9237185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
